Susan Bobulsky Sells 1,299 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Susan Bobulsky sold 1,299 shares of Adaptive Biotechnologies stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $24.00, for a total value of $31,176.00. Following the completion of the transaction, the insider owned 399,989 shares of the company’s stock, valued at approximately $9,599,736. This trade represents a 0.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Susan Bobulsky also recently made the following trade(s):

• On Wednesday, July 1st, Susan Bobulsky sold 487 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $22.00, for a total value of $10,714.00.
• On Thursday, June 11th, Susan Bobulsky sold 5,000 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $19.00, for a total value of $95,000.00.
• On Thursday, June 4th, Susan Bobulsky sold 11,000 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $18.00, for a total value of $198,000.00.

Adaptive Biotechnologies Stock Performance

Shares of ADPT opened at $24.55 on Wednesday. Adaptive Biotechnologies Corporation has a 1 year low of $10.65 and a 1 year high of $24.62. The stock has a market capitalization of $3.93 billion, a PE ratio of -59.88 and a beta of 2.08. The company has a debt-to-equity ratio of 2.22, a quick ratio of 4.68 and a current ratio of 4.79. The stock has a 50-day simple moving average of $19.82 and a 200-day simple moving average of $16.73.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.12). The firm had revenue of $71.55 million for the quarter, compared to analysts’ expectations of $65.44 million. Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The firm’s quarterly revenue was up 21.5% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.17) earnings per share. On average, analysts predict that Adaptive Biotechnologies Corporation will post -0.41 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Piper Sandler raised their price objective on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a report on Tuesday. Guggenheim increased their target price on Adaptive Biotechnologies from $22.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Friday, July 17th. TD Cowen raised their price target on Adaptive Biotechnologies from $25.00 to $28.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Finally, BTIG Research lifted their price target on Adaptive Biotechnologies from $24.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $24.42.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ADPT. Caitong International Asset Management Co. Ltd purchased a new position in shares of Adaptive Biotechnologies in the 4th quarter valued at $28,000. EverSource Wealth Advisors LLC lifted its position in Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after acquiring an additional 1,565 shares during the last quarter. KBC Group NV acquired a new position in Adaptive Biotechnologies in the first quarter valued at $45,000. Assetmark Inc. boosted its stake in Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after acquiring an additional 2,708 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. purchased a new position in shares of Adaptive Biotechnologies during the fourth quarter worth about $51,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.